A Compassionate use program with Trifluridine/Tipiracil (TAS-102) in patients with a pretreated metastatic colorectal cancer.

Trial Profile

A Compassionate use program with Trifluridine/Tipiracil (TAS-102) in patients with a pretreated metastatic colorectal cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top